Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients?

Kadri Altundag¹

Received: 26 October 2017 / Accepted: 22 November 2017 / Published online: 24 November 2017
© Springer Science+Business Media, LLC, part of Springer Nature 2017

Dear Editor,

I wish to congratulate Jeong and colleagues for their article [1] in which the characteristics and prognosis of post-transplant breast cancer (PTBC) patients receiving immunosuppressants and general breast cancer patients were compared. They reported that subtype and prognosis of breast cancer were comparable with that in the general cohort and immunosuppressants do not adversely affect breast cancer prognosis. In this study, 24 were diagnosed with PTBC. Of the 24 PTBC cohort, 12 received mammalian target of rapamycin (mTOR) inhibitor—tacrolimus as immunosuppressive agent. Results of both the TAMRAD and BOLERO-2 studies showed that mTOR inhibition in combination with endocrine therapy improved progression-free survival for hormone receptor-positive metastatic breast cancer patients [2]. For this reason, it would be interesting to compare the outcome of hormone receptor-positive PTBC patients who received endocrine treatment and tacrolimus with hormone receptor-positive patients in general cohort.

Acknowledgements The author has not received any grants.

Compliance with ethical standards

Conflict of interest I have no conflict of interest to declare.

Ethical approval My manuscript complies with the Ethical Rules applicable for this journal.

Research involving human and animal participants This article does not contain any studies with human participants or animals performed by the author.

References

1. Jeong IJ, Lee SG, Kim YH, Ko BS, Lee JW, Son BH, Ahn SH, Kim HJ (2017) Characteristics and prognosis of breast cancer after liver or kidney transplantation. *Breast Cancer Res Treat*. <https://doi.org/10.1007/s10549-017-4504-1>
2. Sendur MA, Zengin N, Aksoy S, Altundag K (2014) Everolimus: a new hope for patients with breast cancer. *Curr Med Res Opin* 30(1):75–87. <https://doi.org/10.1185/03007995.2013.846253>

✉ Kadri Altundag
altundag66@yahoo.com

¹ MKA Breast Cancer Clinic, Tepe Prime, Cankaya,
06800 Ankara, Turkey